COMPANY

Asher Biotherapeutics

HQ: South San Francisco, CA source · asherbio.com ↗ · New England

At Asher Biotherapeutics, we are a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. From company website Source · Oct 12, 2026

Keywords: Non Small Cell Lung Cancer Melanoma Squamous Cell Carcinoma of Head and Neck Renal Cell Carcinoma

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $55M · announced Apr 16, 2024 Company release ↗
Source quote
- Apr 16, 2024 · Company release ↗
  “Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials – Proceeds will fund further development of AB248”

Raises announced in these releases: $55M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jan 8, 2025 Partnership Partnership / licensing announced Jan 8, 2025. Source: company's own press page. source ↗
Apr 16, 2024 Raise Series C · $55M source ↗
Jan 4, 2023 Trial start Phase 1: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors source ↗

Funding

Last 2 years.

Jan 8, 2025 Partnership / licensing announced Jan 8, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05653882	A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors	Phase 1	Active, not recruiting	Jan 4, 2023	2026-08 (estimated)